Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy
Interventions: BT-600, BT-600 Placebo; Combination Product
Lead sponsor: Biora Therapeutics, Inc.; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hypertension, Mineralocorticoid Receptor Antagonist
Interventions: CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Intra-epidermal stimulation electrode; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteer
Interventions: ABBV-1042, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: MRT-6160, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: FXI
Interventions: FXI-GalNAc-siRNA, Placebo; Drug · Other
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Creve Coeur, Missouri

Conditions: Healthy Volunteer
Interventions: Placebo, PF-04958242; Drug
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Pharmacokinetics
Interventions: Nafamostat Mesilate, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: Diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: APOL1-mediated Kidney Disease
Interventions: VX-840, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet, Placebo; Drug · Other
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Tramadol HCl, 50 mg, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy, Alzheimer Disease
Interventions: Lu AF87908, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Glendale, California • Hollywood, Florida • Miami, Florida + 3 more

Conditions: Healthy
Interventions: HF1K16, Placebo; Drug
Lead sponsor: HighField Biopharmaceuticals Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Acinetobacter Baumannii Infection
Interventions: ETX2514SUL; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota

Conditions: Healthy
Interventions: JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, JNJ-54861911-Matched Placebo, Moxifloxacin, Moxifloxacin Matched Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Subjects
Interventions: SKI-606, Placebo, Moxifloxacin; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy Volunteer
Interventions: Placebo, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Eatontown, New Jersey

Conditions: Healthy
Interventions: TD-0714, Placebo Comparator; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity
Interventions: AMG 786, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Tustin, California • Aventura, Florida • Miami, Florida

Conditions: Celiac Disease
Interventions: ALV003, Placebo; Drug
Lead sponsor: Alvine Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: AZD8683, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

First-in-human Study of MRT-6160 in Healthy Subjects

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

Oral Nafamostat in Healthy Volunteers (NAF-101)

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

AZD8683 Single Ascending Dose Study

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers